Term ends no later than Dec 17, 2041 · Medium confidence
20-year base term ends Nov 1, 2039
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Held by Medic Life Sciences, Inc.
Filed Apr 29, 2021 as application 17/289,861 · Granted Mar 4, 2025
Base term plus 777 days of patent term adjustment (USPTO delay)
Today
2019
2041
Clock starts
Nov 1, 2019
Nov 1, 2019
Ends no later than
Dec 17, 2041
Dec 17, 2041
Granted
Mar 4, 2025
Mar 4, 2025
base term
patent term adjustment
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
777
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
0 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
4
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 777 days past its 20-year base term on prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. 0 of 3 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 1, 2019, when application PCT/US2019/059542, the earliest non-provisional in its chain, was filed (this one was filed Apr 29, 2021) | Nov 1, 2039 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +777 days, USPTO patent term adjustment record | Dec 17, 2041 | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Dec 17, 2041 | Medium confidence |
This family
| Application PCT/US2019/059542 | PCT application no patent term | no patent term |
| US 10,738,067 | In force Nov 2039 | Nov 2039 |
| US 12,240,869 | this patent no later than Dec 2041 | no later than Dec 2041 |
| Application 19/037,690 | Pending not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 5, 2024 Reel 69516, frame 338 | Syros Pharmaceuticals, Inc.; Tyme Technologies, Inc.; Tyme Inc. | Oxford Finance LLC, as Collateral Agent | Security Interest |
| Jan 15, 2025 Reel 69882, frame 421 | Ciblat, Stephane; Kabro, Anzhelika | Paraza Pharma, Inc. | Assignment of Assignor's Interest |
| Jan 15, 2025 Reel 69882, frame 642 | Marineau, Jason J.; Bradley, Michael; Chuaqui, Claudio | Syros Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Jan 15, 2025 Reel 69882, frame 748 | Paraza Pharma, Inc. | Syros Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Mar 5, 2025 Reel 70414, frame 140 | Syros Pharmaceuticals, Inc. | Oxford Finance LLC | Assignment of Assignor's Interest |
| Sep 18, 2025 Reel 72304, frame 490 | Oxford Finance LLC | Medic Life Sciences, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Dec 2041
Term ends no later than Dec 17, 2041. Maintenance fees still fall due before then
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Note
The 777 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Dec 17, 2041. We will not guess the cap.
Citations
0
later US patents cite this one
Fewer than half of the utility patents granted in 2025 in our data have been cited yet, so we show the count and do not rank on it.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.